Business Standard

US FDA advisers back Pfizer-BioNTech Covid-19 vaccine for children

The companies have said their vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of children aged 5 to 11

Coronavirus vaccine
Premium

Pfizer and BioNTech are seeking clearance for a lower, 10-microgram dose of the vaccine in children, versus 30 micrograms for those age 12 and older

Manas Mishra and Michael Erman | Reuters
An expert panel on Tuesday voted overwhelmingly to recommend the US Food and Drug Administration authorize the Pfizer Inc and BioNTech SE Covid-19 vaccine for children ages 5 to 11, saying the benefits of inoculation outweigh the risks.

An authorization for that age group would be would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.

The vaccine could be available to the younger age group as soon as next week. The FDA is not obligated to follow the advice of its outside experts, but usually does.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 27 2021 | 3:14 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com